Clinical Therapeutics E. D. Pieterman, S. van den Berg, A. van der Meijden, E. M. Svensson, H. I. Bax, J. E. M. de Steenwinkel DOI: 10.1128/AAC.02255-20 ABSTRACT Improvements in the translational value of preclinical models can allow more-successful and more-focused research on shortening the duration of tuberculosis treatment. Although the hollow-fiber infection model (HFIM) is considered a valuable addition to the drug development pipeline, its exact role has not been fully determined yet.